We've got a couple catalysts coming down the pike; first the announcement of enrollment for P2, then the kickoff of the trials. With a float of somewhere around 17 million, if I added the right numbers, the kind of interest we saw the last month will return. That's an awfully small OS for an innovative therapy in P2. And we've got the looming possibility that industry matchmaking leader Wainwright will find ampliphi a suitor. Hoping for a yuge dip to load up on.
News 
Market Data 
Discover 
